Filter Results
Filter Results
Partnerships (17) General (16) Media Advisory (16) New Technologies (9)
2026 (6) 2025 (5) 2024 (3) 2023 (2) 2022 (8) 2021 (5) 2020 (3) 2019 (4) 2018 (3) 2017 (1) 2016 (2)
English (42)
EnglishX
Reset Filters
   Loading...
Showing 1‐10 of 42
Media Advisory
15 Jun 2026
Lonza Grants Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers
Target-specific licensing agreement enabling Antharis to advance proprietary dual-payload antibody-drug conjugate (ADC) programs using Lonza’s site-specific...
Media Advisory
09 Jun 2026
AmMax Bio Licenses Antibody-Drug Conjugate Technology for Hematological Cancers from Lonza
New agreement provides AmMax with access to Lonza’s GlycoConnect®, HydraSpace®, and SYNtecan™ linker-payload technologies Agreement to target development of novel...
Media Advisory
04 Jun 2026
Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies
Multi-target agreement positions Stipple Bio to advance next-generation ADC therapies using Lonza’s clinically validated ADC platform Stipple Bio’s Pointillist Platform...
Media Advisory
07 May 2026
Bristol Myers Squibb Licenses Antibody-Drug Conjugate Technology from Lonza
Agreement grants Bristol Myers Squibb (BMS) access to the SYNtecan™ linker-payload platform, along with GlycoConnect® and HydraSpace® technologies Basel, Switzerland, and...
Media Advisory
31 Mar 2026
Swiss Rockets Collaborates with Lonza to Advance Torqur’s Oncology Drug Candidate Bimiralisib into Late-Stage Clinical Development
Lonza collaborates with a biotech innovator to advance a promising oncology drug candidate, bimiralisib cGMP manufacturing to be provided at Lonza’s Highly Potent Active...
Media Advisory
19 Feb 2026
Lonza Strengthens Advanced Synthesis Capabilities to Lead Bioconjugates Innovation and Development
Lonza strengthens its integrated Advanced Synthesis offering with industry-leading early-phase bioconjugates development capabilities and payload and linker technologies The...
Media Advisory
07 Jul 2025
Lonza Launches Next Generation 4D-Nucleofector® LV Unit PRO for Improved Electroporation in GMP Manufacturing
Launch enables efficient and scalable electroporation across research applications up to GMP manufacturing New system includes optimized cartridge design for improved...
Media Advisory
22 May 2025
Lonza Launches Design2Optimize® Platform to Streamline API Development
New model-based platform designed to accelerate process development of active pharmaceutical ingredients (APIs) The Design2Optimize® platform contributes to improved...
Media Advisory
14 Apr 2025
Lonza joins Centre for Continuous Manufacturing and Advanced Crystallisation to Enhance Service Offering
Lonza joined CMAC to enhance its service offering for specialty and enhanced drug product and particle technologies   Lonza will serve as a CMAC Translation to Industry...
Media Advisory
07 Apr 2025
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention
Formulations to be developed at Lonza’s Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US), in accordance with current Good Manufacturing...
1 2 3 4 ... 5 >